# pancreatic cancer临床试验报告

**生成日期**: 2025-06-07
**数据来源**: ClinicalTrials.gov API v2
**查询条件**: pancreatic cancer相关的活跃临床试验
**总计试验数**: 29
**本次显示**: 29 个试验

---

## 试验列表

### 正在招募 (29 个试验)


#### Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

- **试验编号**: NCT06897644
- **状态**: RECRUITING
- **适应症**: Pancreatic Adenocarcinoma Advanced or Metastatic
- **干预措施**: Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
- **申办方**: Gruppo Oncologico del Nord-Ovest
- **研究地点**: Centro Di Riferimento Oncologico Di Aviano, Aviano, Italy; University Hospital Consorziale Policlinico, Bari, Italy; Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
- **开始日期**: 2025-03-27
- **首次提交**: 2025-03-20
- **主要研究者**: Monica Niger, MD (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano)
- **入组标准**: Inclusion Criteria:

* Patient able and willing to provide written informed consent and to comply with the study protocol.
* Subjects must be ≥18 years.
* Histologically or cytologically confirmed unr...
- **详细信息**: https://clinicaltrials.gov/study/NCT06897644

---


#### A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

- **试验编号**: NCT06907043
- **状态**: RECRUITING
- **适应症**: Advanced Solid Tumors
- **干预措施**: EIK1004-001 (IMP1707-001)
- **申办方**: Eikon Therapeutics
- **研究地点**: MD Anderson, Houston, United States; Fudan University Shanghai Cancer Center, Shanghai, China
- **开始日期**: 2025-05-12
- **首次提交**: 2025-03-22
- **主要研究者**: Yawei Zhang, MD (Eikon Therapeutics)
- **入组标准**: • Breast cancer: must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+, HGSOC or high grade endometrioid EOC, fallop...
- **详细信息**: https://clinicaltrials.gov/study/NCT06907043

---


#### A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

- **试验编号**: NCT06898385
- **状态**: RECRUITING
- **适应症**: Pancreatic Cancer
- **干预措施**: IX001 TCR-T injection, Fludarabine, Cyclophosphamide
- **申办方**: Sun Yat-sen University
- **研究地点**: Sun Yat-sen University Cancer Center, Guangzhou, China
- **开始日期**: 2025-03-27
- **首次提交**: 2025-03-21
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

* 1\. Voluntary signing of an informed consent form (for Human Leukocyte Antigen (HLA) typing and tumor gene mutation test, and main screening)
* 2\. Males or females, aged 18-75 ...
- **详细信息**: https://clinicaltrials.gov/study/NCT06898385

---


#### A Study to Learn More About How Well Treatment With BAY2927088 Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

- **试验编号**: NCT06760819
- **状态**: RECRUITING
- **适应症**: Advanced Solid Tumors, HER2 Mutation
- **干预措施**: BAY2927088
- **申办方**: Bayer
- **研究地点**: University of Alabama at Birmingham, Birmingham, United States; City of Hope - Duarte Cancer Center, Duarte, United States; Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers, United States
- **开始日期**: 2025-02-13
- **首次提交**: 2024-12-18
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

* Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor cancer (colorectal carcinoma; biliary tract cancer; bladder and uro...
- **详细信息**: https://clinicaltrials.gov/study/NCT06760819

---


#### A Study of MT-4561 in Patients With Various Advanced Solid Tumors

- **试验编号**: NCT06943521
- **状态**: RECRUITING
- **适应症**: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, NUT Carcinoma
- **干预措施**: MT-4561
- **申办方**: Mitsubishi Tanabe Pharma America Inc.
- **研究地点**: START Midwest, Grand Rapids, United States; The University of Texas MD Anderson Cancer Center, Houston, United States
- **开始日期**: 2025-04-18
- **首次提交**: 2025-03-28
- **主要研究者**: Head of Medical Science (Mitsubishi Tanabe Pharma America Inc.)
- **入组标准**: Main Inclusion Criteria:

* Male or female patient aged 18 years or older at the time of signing the informed consent form
* ≥ 1 measurable lesion by the RECIST v1.1 and ≥ 1 disease site for tumor bio...
- **详细信息**: https://clinicaltrials.gov/study/NCT06943521

---


#### A Phase II Nationwide, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR Genetic Alterations

- **试验编号**: NCT06906562
- **状态**: RECRUITING
- **适应症**: Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- **干预措施**: Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging, Optical Coherence Tomography, Bone Scan, Ophthalmoscopy
- **申办方**: Sameek Roychowdhury
- **研究地点**: Ohio State University Comprehensive Cancer Center, Columbus, United States
- **开始日期**: 2025-06-01
- **首次提交**: 2025-03-26
- **主要研究者**: Sameek Roychowdhury, MD, PhD (Ohio State University Comprehensive Cancer Center)
- **入组标准**: Inclusion Criteria

Patients with histologically or cytologically confirmed advanced or metastatic pancreatic cancer of any histologic classification at the time of diagnosis

* Written documentation ...
- **详细信息**: https://clinicaltrials.gov/study/NCT06906562

---


#### A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

- **试验编号**: NCT06782555
- **状态**: RECRUITING
- **适应症**: Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- **干预措施**: Evofosfamide, Zalifrelimab, Balstilimab
- **申办方**: ImmunoGenesis
- **研究地点**: MD Anderson Cancer Center, Houston, United States
- **开始日期**: 2025-01-08
- **首次提交**: 2025-01-09
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

1. Histologically confirmed locally advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, or HPV-negative SCCHN for which no other lines of standard ther...
- **详细信息**: https://clinicaltrials.gov/study/NCT06782555

---


#### A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

- **试验编号**: NCT06818812
- **状态**: RECRUITING
- **适应症**: Solid Tumors
- **干预措施**: INCB186748, Cetuximab, GEMNabP, mFOLFIRINOX
- **申办方**: Incyte Corporation
- **研究地点**: UCLA Healthcare Hematology-Oncology, Santa Monica, United States; Sarah Cannon Research Institue At Healthone, Denver, United States; Georgetown University Hospital, Washington D.C., United States
- **开始日期**: 2025-03-27
- **首次提交**: 2025-02-05
- **主要研究者**: Incyte Medical Monitor (Incyte Corporation)
- **入组标准**: Inclusion Criteria:

* ≥18 years old.
* Locally advanced or metastatic solid tumor with KRAS G12D mutation.
* For Part 1 and Part 2 Combination Group 1: Disease progression on or after prior standard ...
- **详细信息**: https://clinicaltrials.gov/study/NCT06818812

---


#### A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

- **试验编号**: NCT06789172
- **状态**: RECRUITING
- **适应症**: Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, NSCLC, Pancreatic Adenocarcinoma, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
- **干预措施**: OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist
- **申办方**: Epkin
- **研究地点**: Precision NextGen Oncology and Research Center, Beverly Hills, United States; Sarcoma Oncology Center, Santa Monica, United States; Chris O'Brien Lifehouse, Sydney, Australia
- **开始日期**: 2025-01-23
- **首次提交**: 2025-01-13
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

1. Histologically or cytologically confirmed disease, locally advanced or metastatic:

   For Phase 1a:

   Solid tumor with a COX2-associated immunosuppressive pathway, for which...
- **详细信息**: https://clinicaltrials.gov/study/NCT06789172

---


#### A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

- **试验编号**: NCT06944106
- **状态**: RECRUITING
- **适应症**: Pancreatic Cancer
- **干预措施**: AK112
- **申办方**: Tianjin Medical University Cancer Institute and Hospital
- **研究地点**: Tianjin Cancer Hospital Airport Hospital, Tianjin, China
- **开始日期**: 2025-03-28
- **首次提交**: 2025-04-17
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

1. Age ≥ 18 years and ≤ 75 years.
2. Histologically or cytologically confirmed pancreatic cancer.
3. Borderline resectable disease.
4. At least one measurable lesion (according to...
- **详细信息**: https://clinicaltrials.gov/study/NCT06944106

---


#### DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

- **试验编号**: NCT06757244
- **状态**: RECRUITING
- **适应症**: Pancreas Neoplasms
- **干预措施**: Dostarlimab, Vitamin D3 (Cholecalciferol), mFOLFIRINOX Treatment Regimen, LV5FU2
- **申办方**: Hopital Foch
- **研究地点**: Marseille CRLCC, Marseille, France; CHU Hôtel Dieu, Nantes, France; Hôpital Européen Georges Pompidou, Paris, France
- **开始日期**: 2025-02-18
- **首次提交**: 2024-11-27
- **主要研究者**: Jaafar BENNOUNA, Pr (Hôpital Foch)
- **入组标准**: Inclusion criteria

1. Histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas
2. No prior treatment for stage IV pancreatic adenocarcinoma (prior adjuvant or neoadjuvant treatment...
- **详细信息**: https://clinicaltrials.gov/study/NCT06757244

---


#### A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

- **试验编号**: NCT06882746
- **状态**: RECRUITING
- **适应症**: Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- **干预措施**: BI 765049
- **申办方**: Boehringer Ingelheim
- **研究地点**: Valkyrie Clinical Trials, Los Angeles, United States; Yale Cancer Center, New Haven, United States; Winship Cancer Institute, Atlanta, United States
- **开始日期**: 2025-03-28
- **首次提交**: 2025-03-17
- **主要研究者**: N/A
- **入组标准**: Inclusion criteria:

* Signed and dated informed consent form (ICF)2/main ICF for all patients describing the study in accordance with International Council on Harmonisation Good Clinical Practice (IC...
- **详细信息**: https://clinicaltrials.gov/study/NCT06882746

---


#### BBO-11818 in Adult Subjects With KRAS Mutant Cancer

- **试验编号**: NCT06917079
- **状态**: RECRUITING
- **适应症**: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
- **干预措施**: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab
- **申办方**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **研究地点**: Sarah Cannon Research Institute at Mary Crowley, Dallas, United States; The University of Texas MD Anderson Cancer Center, Houston, United States; NEXT Oncology, San Antonio, United States
- **开始日期**: 2025-03-31
- **首次提交**: 2025-04-01
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

* Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation, or KRAS-ampl...
- **详细信息**: https://clinicaltrials.gov/study/NCT06917079

---


#### Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

- **试验编号**: NCT06844422
- **状态**: RECRUITING
- **适应症**: Pancreatic Cancer
- **干预措施**: Ivonescimab
- **申办方**: Shandong Cancer Hospital and Institute
- **研究地点**: Shandong Cancer Hospital and Institute, Jinan, China
- **开始日期**: 2025-02-08
- **首次提交**: 2025-02-19
- **主要研究者**: Jinbo Yue, Doctor (Shandong Cancer Hospital and Institute)
- **入组标准**: Inclusion Criteria:

1. Pathologically or cytologically confirmed unresectable LAPC, as defined by the 8th edition of the American Joint Committee on Cancer (AJCC);
2. Age between 18 and 80 years;
3. ...
- **详细信息**: https://clinicaltrials.gov/study/NCT06844422

---


#### Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

- **试验编号**: NCT06861452
- **状态**: RECRUITING
- **适应症**: Locally Advanced Pancreatic Adenocarcinoma
- **干预措施**: RR001
- **申办方**: EIR Biotherapies s.r.l.
- **研究地点**: Azienda Ospedaliero-Universitaria (AOU) Policlinico di Modena, Modena, Italy
- **开始日期**: 2025-05
- **首次提交**: 2025-01-28
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

* Patients with confirmed pancreatic ductal adenocarcinoma classified as locally advanced pancreatic adenocarcinoma (LPAC)
* Patients with no evidence of peritoneal or hematogenou...
- **详细信息**: https://clinicaltrials.gov/study/NCT06861452

---


#### Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

- **试验编号**: NCT06831136
- **状态**: RECRUITING
- **适应症**: Pancreatic Ductal Adenocarcinoma
- **干预措施**: Neoadjuvant Chemotherapy (NAC), Immunotherapy (pembrolizumab), Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
- **申办方**: The University of Texas Health Science Center, Houston
- **研究地点**: The University of Texas Health Science Center at Houston, Houston, United States
- **开始日期**: 2025-03-26
- **首次提交**: 2025-01-16
- **主要研究者**: Putao Cen (The University of Texas Health Science Center, Houston)
- **入组标准**: Inclusion Criteria:

* Is willing and able to comply with the protocol for the duration of the study,including undergoing treatment and scheduled visits and examinations, including follow-up
* Biopsy-...
- **详细信息**: https://clinicaltrials.gov/study/NCT06831136

---


#### CT-95 in Advanced Cancers Associated With Mesothelin Expression

- **试验编号**: NCT06756035
- **状态**: RECRUITING
- **适应症**: Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
- **干预措施**: CT-95
- **申办方**: Context Therapeutics Inc.
- **研究地点**: Context Investigational Site, Hackensack, United States; Context Investigational Site, San Antonio, United States
- **开始日期**: 2025-03-31
- **首次提交**: 2024-12-18
- **主要研究者**: Karen Smith, MD, PhD, MBA, LLM (Context Therapeutics Inc.)
- **入组标准**: Inclusion Criteria:

* ECOG 0 or 1
* Subjects with evaluable disease per RECIST 1.1 or mRECIST
* Subjects with adequate organ function.
* Subjects with advanced cancers associated with mesothelin expr...
- **详细信息**: https://clinicaltrials.gov/study/NCT06756035

---


#### CAR-NK Cells (CL-NK-001) in Pancreatic Cancer

- **试验编号**: NCT06816823
- **状态**: RECRUITING
- **适应症**: Pancreatic Cancer
- **干预措施**: CL-NK-001
- **申办方**: Changhai Hospital
- **研究地点**: Changhai Hospital, Shanghai, China
- **开始日期**: 2025-04-07
- **首次提交**: 2025-02-01
- **主要研究者**: Zhuan Liao, MD PhD (Changhai Hospital)
- **入组标准**: Inclusion Criteria:

1. Aged 18-70 years;
2. Locally advanced, metastatic, or recurrent pancreatic cancer, with immunohistochemical detection of eGR1 (membrane positive tumor cell rate \>40% and expre...
- **详细信息**: https://clinicaltrials.gov/study/NCT06816823

---


#### A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

- **试验编号**: NCT06778863
- **状态**: RECRUITING
- **适应症**: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
- **干预措施**: CLSP-1025
- **申办方**: Clasp Therapeutics, Inc.
- **研究地点**: USC - Norris Comprehensive Cancer Center, Los Angeles, United States; NYU Langone Health, New York, United States; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, United States
- **开始日期**: 2025-02-28
- **首次提交**: 2025-01-08
- **主要研究者**: N/A
- **入组标准**: Key Inclusion Criteria:

* Patients must be at least 18 years of age at the time of signing the informed consent.
* Patients must be willing and able to provide written informed consent
* Patients mus...
- **详细信息**: https://clinicaltrials.gov/study/NCT06778863

---


#### Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

- **试验编号**: NCT06922591
- **状态**: RECRUITING
- **适应症**: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
- **干预措施**: TNG462, RMC-9805, RMC-6236
- **申办方**: Tango Therapeutics, Inc.
- **研究地点**: NEXT Oncology, Fairfax, United States
- **开始日期**: 2025-05-31
- **首次提交**: 2025-03-28
- **主要研究者**: Maeve Waldron-Lynch, MD (Tango Therapeutics, Inc.)
- **入组标准**: Inclusion Criteria:

1. Is ≥18 years of age at the time of signature of the main study ICF.
2. Has an ECOG PS of 0 or 1.
3. Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gen...
- **详细信息**: https://clinicaltrials.gov/study/NCT06922591

---


#### A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism

- **试验编号**: NCT06881992
- **状态**: RECRUITING
- **适应症**: Tumor- Associated Hyperinsulinism
- **干预措施**: Ersodetug, Ersodetug, Placebo
- **申办方**: Rezolute
- **研究地点**: Investigative Site, Canton, United States
- **开始日期**: 2025-04-16
- **首次提交**: 2025-03-10
- **主要研究者**: N/A
- **入组标准**: Double-Blind Arm: (Ambulatory ICT and Ambulatory NICT participants)

Inclusion Criteria:

* The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI whi...
- **详细信息**: https://clinicaltrials.gov/study/NCT06881992

---


#### A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

- **试验编号**: NCT06999187
- **状态**: RECRUITING
- **适应症**: Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
- **干预措施**: DR-0202
- **申办方**: Dren Bio
- **研究地点**: Dren Investigational Site, Denver, United States; Dren Investigational Site, Orlando, United States; Dren Investigational Site, Sarasota, United States
- **开始日期**: 2025-06
- **首次提交**: 2025-05-12
- **主要研究者**: Wan Jen Hong, MD (Dren Bio)
- **入组标准**: Inclusion Criteria:

* Histologically confirmed epithelial cancer of the following tumor types: breast (TNBC, HR+/HER2-/+BC), NSCLC, cervical, CRPC, PDAC, HNSCC, endometrial, ovarian, gastric/GEJ, or ...
- **详细信息**: https://clinicaltrials.gov/study/NCT06999187

---


#### Study for AZD4360 in Participants With Advanced Solid Tumours

- **试验编号**: NCT06921928
- **状态**: RECRUITING
- **适应症**: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- **干预措施**: AZD4360
- **申办方**: AstraZeneca
- **研究地点**: Research Site, Los Angeles, United States; Research Site, Providence, United States; Research Site, Houston, United States
- **开始日期**: 2025-04-29
- **首次提交**: 2025-03-25
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

1. Participant must be ≥ 18 at the time of signing the ICF.
2. Eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior t...
- **详细信息**: https://clinicaltrials.gov/study/NCT06921928

---


#### A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

- **试验编号**: NCT06835569
- **状态**: RECRUITING
- **适应症**: Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
- **干预措施**: ALTA3263
- **申办方**: Alterome Therapeutics, Inc.
- **研究地点**: Research Site, Boston, United States; Research Site, Nashville, United States; Research Site, Houston, United States
- **开始日期**: 2025-03-05
- **首次提交**: 2025-02-14
- **主要研究者**: Study Medical Director (Alterome Therapeutics)
- **入组标准**: Inclusion Criteria:

* Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Impr...
- **详细信息**: https://clinicaltrials.gov/study/NCT06835569

---


#### Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

- **试验编号**: NCT06914674
- **状态**: RECRUITING
- **适应症**: Pancreatic Neoplasms
- **干预措施**: Tamoxifen 20 mg
- **申办方**: Fudan University
- **研究地点**: Shanghai Cancer Center, Shanghai, China
- **开始日期**: 2025-03-20
- **首次提交**: 2025-03-31
- **主要研究者**: Guopei Luo Prof, MD (Shanghai Cancer Center)
- **入组标准**: Inclusion Criteria:

1. Age 14-80 years.
2. Histologically confirmed advanced SPTP with ER/PR+.
3. Advanced disease:

   * Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, et...
- **详细信息**: https://clinicaltrials.gov/study/NCT06914674

---


#### The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

- **试验编号**: NCT06946901
- **状态**: RECRUITING
- **适应症**: Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Metastatic Pancreatic Cancer
- **干预措施**: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy
- **申办方**: Shanghai Zhongshan Hospital
- **研究地点**: The Second Xiangya Hospital of Central South University, Changsha, China; Zhongshan Hospital, Fudan University, Shanghai, China
- **开始日期**: 2025-04-03
- **首次提交**: 2025-04-19
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

* Obtain signed informed consent from the patient or their legal representative, with adherence to the study protocol and follow-up procedures;
* Aged \>=18 and \<=80 years, regar...
- **详细信息**: https://clinicaltrials.gov/study/NCT06946901

---


#### Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

- **试验编号**: NCT06789679
- **状态**: RECRUITING
- **适应症**: Pancreatic Adenocarcinoma
- **干预措施**: Gemcitabine, albumin-bound paclitaxel, S-1, Gemcitabine, albumin-bound paclitaxel
- **申办方**: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **研究地点**: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- **开始日期**: 2025-01-25
- **首次提交**: 2025-01-17
- **主要研究者**: Lin Yang, Prof (LIN YA Cancer Institute and Hospital, Chinese Academy of Medical Sciences)
- **入组标准**: Inclusion Criteria:

The participant must voluntarily agree to participate in the study and sign the informed consent form.

The participant must be ≥18 years old on the day of signing the informed co...
- **详细信息**: https://clinicaltrials.gov/study/NCT06789679

---


#### Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

- **试验编号**: NCT06782412
- **状态**: RECRUITING
- **适应症**: Oesophageal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, FAP, Oncology, Oncologic Disorders
- **干预措施**: [18F]AlF-FAPI-74 PET/CT
- **申办方**: KU Leuven
- **研究地点**: University Hospital Antwerp (UZA), Edegem, Belgium; University Hospital Ghent, Ghent, Belgium; UZ Leuven, Leuven, Belgium
- **开始日期**: 2025-02-06
- **首次提交**: 2025-01-06
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria OGA:

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
2. Age 18 or older.
3....
- **详细信息**: https://clinicaltrials.gov/study/NCT06782412

---


#### A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

- **试验编号**: NCT06962267
- **状态**: RECRUITING
- **适应症**: Pancreatic Cancer
- **干预措施**: TQB2916 Injection, Chemotherapy
- **申办方**: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **研究地点**: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
- **开始日期**: 2025-04-18
- **首次提交**: 2025-04-30
- **主要研究者**: N/A
- **入组标准**: Inclusion Criteria:

* The subjects voluntarily joined this study and signed the informed consent form;
* Age: 18-75 years old (the time of signing the informed consent form, including the critical va...
- **详细信息**: https://clinicaltrials.gov/study/NCT06962267

---

